Literature DB >> 15726253

High specificity of myositis specific autoantibodies for myositis compared with other neuromuscular disorders.

G J D Hengstman1, L van Brenk, W T M Vree Egberts, E L van der Kooi, G F Borm, G W A M Padberg, W J van Venrooij, B G M van Engelen.   

Abstract

Myositis specific autoantibodies (MSAs) are proven to be specific for myositis compared with other inflammatory connective tissue diseases. Their specificity compared, however, with other neuromuscular disorders, which are included in the differential diagnosis of patients in whom the diagnosis myositis is under consideration, is unknown. We prospectively screened sera from 107 patients with various neuromuscular disorders for the most common MSAs and compared the results with the findings in a group of 97 myositis patients, published previously. Special attention was paid to patients with facioscapulohumeral muscular dystrophy (FSHD), an autosomal dominant muscle disease with marked inflammation in skeletal muscle tissue. Only one patient in the neuromuscular disorders group tested positive for an MSA, compared with 41 in the myositis group, resulting in a specificity of 99%. None of the FSHD patients tested positive. We conclude that the tested MSAs are highly specific for myositis and that they are not merely associated with muscle inflammation.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15726253     DOI: 10.1007/s00415-005-0683-5

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  15 in total

1.  Autoantibody profiles in the sera of European patients with myositis.

Authors:  R Brouwer; G J Hengstman; W Vree Egberts; H Ehrfeld; B Bozic; A Ghirardello; G Grøndal; M Hietarinta; D Isenberg; J R Kalden; I Lundberg; H Moutsopoulos; P Roux-Lombard; J Vencovsky; A Wikman; H P Seelig; B G van Engelen ; W J van Venrooij
Journal:  Ann Rheum Dis       Date:  2001-02       Impact factor: 19.103

2.  Inflammatory changes in facioscapulohumeral muscular dystrophy.

Authors:  M Molnár; P Diószeghy; F Mechler
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  1991       Impact factor: 5.270

3.  Sensitivity and specificity of anti-Jo-1 antibodies in autoimmune diseases with myositis.

Authors:  D Vázquez-Abad; N F Rothfield
Journal:  Arthritis Rheum       Date:  1996-02

4.  Frequent occurrence of anti-tRNA(His) autoantibodies that recognize a conformational epitope in sera of patients with myositis.

Authors:  R Brouwer; W Vree Egberts; P H Jongen; B G van Engelen; W J van Venrooij
Journal:  Arthritis Rheum       Date:  1998-08

5.  Interstitial lung disease with autoantibodies against aminoacyl-tRNA synthetases in the absence of clinically apparent myositis.

Authors:  A W Friedman; I N Targoff; F C Arnett
Journal:  Semin Arthritis Rheum       Date:  1996-08       Impact factor: 5.532

6.  Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses.

Authors:  K Arahata; T Ishihara; H Fukunaga; S Orimo; J H Lee; K Goto; I Nonaka
Journal:  Muscle Nerve Suppl       Date:  1995

7.  Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.

Authors:  G J D Hengstman; R Brouwer; W T M Vree Egberts; H P Seelig; P J H Jongen; W J van Venrooij; B G van Engelen
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

Review 8.  Polymyositis and dermatomyositis.

Authors:  Marinos C Dalakas; Reinhard Hohlfeld
Journal:  Lancet       Date:  2003-09-20       Impact factor: 79.321

9.  Anti-signal recognition particle autoantibody in patients with and patients without idiopathic inflammatory myopathy.

Authors:  Amy H Kao; David Lacomis; Mary Lucas; Noreen Fertig; Chester V Oddis
Journal:  Arthritis Rheum       Date:  2004-01

10.  A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups.

Authors:  L A Love; R L Leff; D D Fraser; I N Targoff; M Dalakas; P H Plotz; F W Miller
Journal:  Medicine (Baltimore)       Date:  1991-11       Impact factor: 1.889

View more
  9 in total

Review 1.  Myositis specific autoantibodies.

Authors:  Ira N Targoff
Journal:  Curr Rheumatol Rep       Date:  2006-06       Impact factor: 4.592

2.  Disease specificity of autoantibodies to cytosolic 5'-nucleotidase 1A in sporadic inclusion body myositis versus known autoimmune diseases.

Authors:  Megan K Herbert; Judith Stammen-Vogelzangs; Marcel M Verbeek; Anke Rietveld; Ingrid E Lundberg; Hector Chinoy; Janine A Lamb; Robert G Cooper; Mark Roberts; Umesh A Badrising; Jan L De Bleecker; Pedro M Machado; Michael G Hanna; Lenka Plestilova; Jiri Vencovsky; Baziel G van Engelen; Ger J M Pruijn
Journal:  Ann Rheum Dis       Date:  2015-02-24       Impact factor: 19.103

3.  Clinical and laboratory features distinguishing juvenile polymyositis and muscular dystrophy.

Authors:  Gulnara Mamyrova; James D Katz; Robert V Jones; Ira N Targoff; Peter A Lachenbruch; Olcay Y Jones; Frederick W Miller; Lisa G Rider
Journal:  Arthritis Care Res (Hoboken)       Date:  2013-12       Impact factor: 4.794

4.  A New Immunodot Assay for Multiplex Detection of Autoantibodies in a Cohort of Italian Patients With Idiopathic Inflammatory Myopathies.

Authors:  Marilina Tampoia; Antonella Notarnicola; Letizia Abbracciavento; Antonietta Fontana; Margherita Giannini; Renè Louis Humbel; Florenzo Iannone
Journal:  J Clin Lab Anal       Date:  2016-04-13       Impact factor: 2.352

5.  Evaluating the diagnostic utility of new line immunoassays for myositis antibodies in clinical practice: a retrospective study.

Authors:  Federica Montagnese; Haris Babačić; Peter Eichhorn; Benedikt Schoser
Journal:  J Neurol       Date:  2019-03-06       Impact factor: 4.849

6.  Polymyositis and dermatomyositis: Disease spectrum and classification.

Authors:  Siba P Raychaudhuri; Anupam Mitra
Journal:  Indian J Dermatol       Date:  2012-09       Impact factor: 1.494

Review 7.  Autoantibodies in polymyositis and dermatomyositis.

Authors:  Anna Ghirardello; Nicola Bassi; Lavinia Palma; Elisabetta Borella; Marta Domeneghetti; Leonardo Punzi; Andrea Doria
Journal:  Curr Rheumatol Rep       Date:  2013-06       Impact factor: 4.686

8.  Myositis-specific autoantibodies are specific for myositis compared to genetic muscle disease.

Authors:  Andrew L Mammen; Livia Casciola-Rosen; Lisa Christopher-Stine; Thomas E Lloyd; Kathryn R Wagner
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-11-19

9.  Congenital muscular dystrophy with inflammation: Diagnostic considerations.

Authors:  Kaumudi Konkay; Meena Angamuthu Kannan; Lokesh Lingappa; Megha S Uppin; Sundaram Challa
Journal:  Ann Indian Acad Neurol       Date:  2016 Jul-Sep       Impact factor: 1.383

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.